|
US5120722A
(en)
|
1984-02-08 |
1992-06-09 |
Hoffmann-La Roche Inc. |
Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
|
|
US4857518A
(en)
|
1984-10-04 |
1989-08-15 |
Wisconsin Alumni Research Foundation |
Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
|
|
US4717721A
(en)
|
1985-05-30 |
1988-01-05 |
Howard W. Bremer |
Sidechain homo-vitamin D compounds with preferential anti-cancer activity
|
|
WO1987000834A1
(en)
|
1985-08-02 |
1987-02-12 |
Leo Pharmaceutical Products Ltd. A/S |
Novel vitamin d analogues
|
|
US5145846A
(en)
|
1988-01-20 |
1992-09-08 |
Hoffmann-La Roche Inc. |
Vitamin D3 analogs
|
|
US4851401A
(en)
|
1988-07-14 |
1989-07-25 |
Wisconsin Alumni Research Foundation |
Novel cyclopentano-vitamin D analogs
|
|
CA1333616C
(en)
|
1989-03-09 |
1994-12-20 |
Hector F. Deluca |
19-nor-vitamin d compounds
|
|
GB8915770D0
(en)
|
1989-07-10 |
1989-08-31 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US4966898A
(en)
|
1989-08-15 |
1990-10-30 |
Merrell Dow Pharmaceuticals Inc. |
4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
|
|
DE4021433A1
(de)
|
1990-07-04 |
1992-01-09 |
Schering Ag |
Antiandrogene mit steroid(3,2-c)pyrazol-struktur
|
|
DE4101953A1
(de)
|
1991-01-19 |
1992-07-23 |
Schering Ag |
23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
|
|
DE4141746A1
(de)
|
1991-12-13 |
1993-06-17 |
Schering Ag |
20-methyl-substituierte vitamin d-derivate
|
|
WO1993020097A1
(en)
|
1992-03-31 |
1993-10-14 |
British Technology Group Ltd. |
17-substituted steroids useful in cancer treatment
|
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
|
US5547947A
(en)
|
1993-03-11 |
1996-08-20 |
Hoffmann-La Roche Inc. |
Methods of treatment
|
|
SG49321A1
(en)
|
1993-09-30 |
1998-05-18 |
British Tech Group |
Synthesis of 17-(3-pyridyl) steroids
|
|
US5688977A
(en)
|
1996-02-29 |
1997-11-18 |
Napro Biotherapeutics, Inc. |
Method for docetaxel synthesis
|
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
US5919815A
(en)
|
1996-05-22 |
1999-07-06 |
Neuromedica, Inc. |
Taxane compounds and compositions
|
|
CA2255615C
(en)
|
1996-05-22 |
2006-08-29 |
Neuromedica, Inc. |
Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
|
|
GB9622590D0
(en)
|
1996-10-30 |
1997-01-08 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US20020128240A1
(en)
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
US20050233958A1
(en)
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
US6087350A
(en)
|
1997-08-29 |
2000-07-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
|
|
ES2368824T3
(es)
|
1998-03-27 |
2011-11-22 |
Oregon Health & Science University |
Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
|
|
US20030083231A1
(en)
|
1998-11-24 |
2003-05-01 |
Ahlem Clarence N. |
Blood cell deficiency treatment method
|
|
AU783992B2
(en)
|
1998-12-23 |
2006-01-12 |
G.D. Searle Llc |
Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
EP1276482B1
(en)
|
2000-03-02 |
2008-01-16 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Combination chemotherapy
|
|
WO2001081364A1
(en)
|
2000-04-24 |
2001-11-01 |
Kyowa Hakko Kogyo Co., Ltd. |
Estra-1,3,5(10)-triene derivatives
|
|
MXPA02011218A
(es)
|
2000-05-15 |
2004-08-19 |
Celgene Corp |
Composiciones y metodos para el tratamiento de cancer.
|
|
EP1676577A1
(en)
|
2000-05-15 |
2006-07-05 |
Celgene Corporation |
Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
|
|
AU2001275423B2
(en)
|
2000-06-09 |
2007-01-11 |
Regulon, Inc. |
Encapsulation of polynucleotides and drugs into targeted liposomes
|
|
AU2000260772A1
(en)
|
2000-07-05 |
2002-01-14 |
Bryan Muehlberger |
Systems and methods of facilitating electronic payment transactions
|
|
WO2002032861A2
(en)
|
2000-10-17 |
2002-04-25 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
DE10061137B4
(de)
|
2000-12-07 |
2016-10-06 |
Takeda Gmbh |
Neue pharmazeutische Zubereitung
|
|
EP1351678A2
(en)
|
2001-01-02 |
2003-10-15 |
Elizabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
|
AU2002338424B2
(en)
|
2001-04-18 |
2005-04-21 |
Euro-Celtique S.A. |
Benzimidazolone compounds
|
|
NZ540233A
(en)
|
2001-04-18 |
2007-02-23 |
Euro Celtique Sa |
Nociceptin analogs for the treatment of pain
|
|
CZ20032849A3
(en)
|
2001-04-18 |
2004-03-17 |
Euro-Celtique S.A. |
Spiropyrazole compounds
|
|
EP2033644A1
(en)
|
2001-04-18 |
2009-03-11 |
Euro-Celtique S.A. |
Spiroindene and spiroindane compounds
|
|
JP2004530684A
(ja)
|
2001-05-10 |
2004-10-07 |
メルク エンド カムパニー インコーポレーテッド |
エストロゲン受容体モジュレーター
|
|
WO2002102783A1
(en)
|
2001-06-19 |
2002-12-27 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6740641B2
(en)
|
2001-07-27 |
2004-05-25 |
Euro-Celtique, S.A. |
Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
|
|
WO2003020699A2
(en)
|
2001-08-30 |
2003-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
AU2002326823B2
(en)
|
2001-09-06 |
2005-12-15 |
Merck Sharp & Dohme Corp. |
17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
|
US7169788B2
(en)
|
2001-10-30 |
2007-01-30 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
CA2465491A1
(en)
|
2001-11-07 |
2003-05-15 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
|
ES2291543T3
(es)
|
2001-12-06 |
2008-03-01 |
MERCK & CO., INC. |
Inhibicion de kinesina mitotica.
|
|
WO2005016236A2
(en)
|
2003-05-06 |
2005-02-24 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
AU2003212882A1
(en)
|
2002-02-01 |
2003-09-02 |
Euro-Celtique S.A. |
2 - piperazine - pyridines useful for treating pain
|
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
|
US6974818B2
(en)
|
2002-03-01 |
2005-12-13 |
Euro-Celtique S.A. |
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
|
|
AU2003211877A1
(en)
|
2002-03-11 |
2003-09-22 |
Takeda Chemical Industries, Ltd. |
Remedies for sex hormone-dependent disease
|
|
JP4394961B2
(ja)
|
2002-04-08 |
2010-01-06 |
メルク エンド カムパニー インコーポレーテッド |
Ａｋｔ活性の阻害剤としての融合キノキサリン誘導体
|
|
EP1927858B1
(en)
|
2002-04-29 |
2013-01-09 |
Euro-Celtique S.A. |
Conformationally constrained peptides that bind the ORL-1 receptor
|
|
AU2003241326B2
(en)
|
2002-05-02 |
2008-05-01 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US7301028B2
(en)
|
2002-06-14 |
2007-11-27 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
|
WO2004002983A2
(en)
|
2002-06-28 |
2004-01-08 |
Euro-Celtique, S.A. |
Therapeutic piperazine derivatives useful for treating pain
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
EP1534336A4
(en)
|
2002-08-15 |
2005-12-14 |
Human Genome Sciences Inc |
ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS
|
|
EP2298315A1
(en)
|
2002-08-28 |
2011-03-23 |
Harbor BioSciences, Inc. |
Therapeutic treatment methods
|
|
US20050101581A1
(en)
|
2002-08-28 |
2005-05-12 |
Reading Christopher L. |
Therapeutic treatment methods 2
|
|
US7157462B2
(en)
|
2002-09-24 |
2007-01-02 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
DE60318092T2
(de)
|
2002-10-23 |
2008-11-27 |
Pantarhei Bioscience B.V. |
Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
|
|
EP1558609A4
(en)
|
2002-10-30 |
2008-05-28 |
Merck & Co Inc |
KINASE INHIBITORS
|
|
US7202259B2
(en)
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
WO2004060488A1
(en)
|
2002-12-17 |
2004-07-22 |
Schering Corporation |
17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
|
EP1583539A2
(en)
|
2003-01-13 |
2005-10-12 |
Cedars-Sinai Medical Center |
Paricalcitol as a chemotherapeutic agent
|
|
TWI330079B
(en)
|
2003-01-15 |
2010-09-11 |
Synta Pharmaceuticals Corp |
Treatment for cancers
|
|
US20050020546A1
(en)
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
MY142655A
(en)
|
2003-06-12 |
2010-12-15 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
|
PL1867644T3
(pl)
|
2003-07-24 |
2009-10-30 |
Euro Celtique Sa |
Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
|
|
CN102442995A
(zh)
|
2003-07-24 |
2012-05-09 |
欧洲凯尔蒂克公司 |
用于治疗或预防疼痛的杂芳基-四氢哌啶基化合物
|
|
US7071333B2
(en)
|
2003-07-30 |
2006-07-04 |
Bristol-Myers Squibb Company |
Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
|
|
PL1942106T3
(pl)
|
2003-08-01 |
2012-02-29 |
Euro Celtique Sa |
Środki lecznicze użyteczne do leczenia bólu
|
|
EP1660436A4
(en)
|
2003-08-27 |
2006-11-22 |
Merck Frosst Canada Ltd |
cathepsin inhibitors
|
|
WO2005030753A2
(en)
|
2003-09-22 |
2005-04-07 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
ES2360152T3
(es)
|
2003-09-22 |
2011-06-01 |
Euro-Celtique S.A. |
Compuestos de fenil-carboxamida útiles para el tratamiento del dolor.
|
|
JP2007508355A
(ja)
|
2003-10-17 |
2007-04-05 |
４・アー・ゼット・アー・バイオサイエンス・ナムローゼ・フエンノートシャップ |
複素環−置換プテリジン誘導体と治療におけるその利用
|
|
US7445794B1
(en)
|
2004-04-29 |
2008-11-04 |
The Regents Of The University Of Colorado |
Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
|
|
US20060003950A1
(en)
|
2004-06-30 |
2006-01-05 |
Bone Care International, Inc. |
Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
|
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
|
US20060030608A1
(en)
|
2004-08-04 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anti aromatase compounds pharmaceutical compositions and uses thereof
|
|
GB0418900D0
(en)
|
2004-08-24 |
2004-09-29 |
Btg Int Ltd |
Novel salt forms
|
|
EP1807058A1
(en)
|
2004-09-10 |
2007-07-18 |
Nitec Pharma Ag |
Tablets with site time-controlled gastrointestinal release of active ingredient
|
|
AR051597A1
(es)
|
2004-11-01 |
2007-01-24 |
Merck & Co Inc |
Moduladores de los receptores de estrogeno
|
|
EP1674479A1
(en)
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
|
WO2006081152A2
(en)
|
2005-01-24 |
2006-08-03 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
NZ563003A
(en)
|
2005-04-27 |
2011-03-31 |
Univ Florida |
Use of a farnesyl transferase inhibitor to enhance autophagic protein degradation in protein conformation disorders
|
|
CA2611735A1
(en)
|
2005-04-28 |
2006-11-02 |
The Regents Of The University Of Colorado |
Therapeutic bifunctional compounds
|
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
|
EP2374451A3
(en)
|
2005-07-27 |
2012-01-25 |
University of Florida Research Foundation, Inc. |
Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
|
|
AU2007232297B2
(en)
|
2006-04-03 |
2012-09-20 |
Msd Italia S.R.L. |
Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
|
|
WO2008039254A2
(en)
|
2006-06-02 |
2008-04-03 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rna nanoparticles and nanotubes
|
|
WO2008005268A1
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
US20080004286A1
(en)
|
2006-06-30 |
2008-01-03 |
Schering Corporation |
Method of Using Substituted Piperidines that Increase P53 Activity
|
|
US20080051375A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
|
|
RS52956B
(sr)
|
2006-08-25 |
2014-02-28 |
Janssen Oncology Inc. |
Kompozicije za tretman kancera
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
EP2081964A4
(en)
|
2006-10-12 |
2012-07-11 |
Univ Johns Hopkins |
ALGINATE AND ALGINATLYASE COMPOSITIONS AND USE METHOD
|
|
EP2081565A2
(en)
|
2006-10-13 |
2009-07-29 |
Reliance Life Sciences Pvt., Ltd. |
Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
|
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
|
CA2677651A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
WO2008109740A2
(en)
|
2007-03-06 |
2008-09-12 |
Colby Pharmaceutical Company |
Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
|
|
US20090124587A1
(en)
|
2007-07-12 |
2009-05-14 |
Auerbach Alan H |
METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
|
EP2240466B1
(en)
|
2008-01-08 |
2015-07-29 |
Merck Sharp & Dohme Limited |
Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
RU2506267C2
(ru)
|
2008-03-31 |
2014-02-10 |
Дженентек, Инк. |
Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
|
|
HUE030372T2
(en)
|
2008-05-07 |
2017-05-29 |
Cardioxyl Pharmaceuticals Inc |
New nitroso compounds as nitroxyl donors and methods for their use
|
|
WO2012009475A1
(en)
|
2010-07-14 |
2012-01-19 |
Oregon Health & Science University |
Methods of treating cancer with inhibition of lysine-specific demethylase 1
|
|
US9314473B2
(en)
|
2011-02-03 |
2016-04-19 |
Pop Test Oncology Limited Liability Company |
System and method for diagnosis and treatment
|
|
JP5804395B2
(ja)
|
2011-02-03 |
2015-11-04 |
ポップ テスト オンコロジー エルエルシー |
診断と治療のためのシステムおよび方法
|
|
LT3305285T
(lt)
*
|
2012-09-26 |
2020-12-10 |
Aragon Pharmaceuticals, Inc. |
Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį
|
|
WO2014089324A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Substituted cyclic compounds and methods of use
|
|
WO2014150000A1
(en)
|
2013-03-21 |
2014-09-25 |
Isp Investments Inc. |
Diacetylene film sensitized with photoinitiator and applications of the film
|
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
|
BR112016002970A2
(pt)
*
|
2013-08-12 |
2017-09-12 |
Tokai Pharmaceuticals Inc |
biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
|
|
US9987275B2
(en)
|
2014-04-23 |
2018-06-05 |
The Brigham And Women's Hospital, Inc. |
Targeting PARP1 for treatment of TSC and cancers
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
EP3230472A4
(en)
|
2014-12-08 |
2018-06-13 |
Myriad Genetics, Inc. |
Methods and materials for predicting response to niraparib
|
|
US9598459B2
(en)
|
2015-08-03 |
2017-03-21 |
Pop Test Oncology Llc |
Pharmaceutical compositions and methods
|
|
HRP20250157T1
(hr)
|
2016-07-29 |
2025-03-28 |
Janssen Pharmaceutica, N.V. |
Niraparib za primjenu u postupku liječenja raka prostate
|
|
US11702443B2
(en)
|
2016-10-04 |
2023-07-18 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
US11040037B2
(en)
|
2016-10-04 |
2021-06-22 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
JOP20190244A1
(ar)
|
2017-04-13 |
2019-10-13 |
Janssen Pharmaceutica Nv |
تركيبة علاجية لسرطان البروستاتا
|
|
JP2020536903A
(ja)
|
2017-10-11 |
2020-12-17 |
ヤンセン オンコロジー，インコーポレイテッド |
アンドロゲン除去療法と共に酢酸アビラテロン及びプレドニゾンを投与することにより前立腺癌を治療する方法
|